Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study

[Introduction] Acromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.

Detalles Bibliográficos
Autores: Venegas Moreno, Eva, Jiménez-Sánchez, Andrés, Remón-Ruiz, Pablo, Dios, Elena, Perea Cortés, Jaime, Hernández-Reina, Celia, Cano, David A., Soto Moreno, Alfonso
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/391046
Acceso en línea:http://hdl.handle.net/10261/391046
Access Level:acceso abierto
Palabra clave:Acromegaly
Cost analysis
Pasireotide
Pegvisomant
Radiotherapy
id ES_7c698dc7b3bf335cde39bdfaae87423d
oai_identifier_str oai:digital.csic.es:10261/391046
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life studyVenegas Moreno, EvaJiménez-Sánchez, AndrésRemón-Ruiz, PabloDios, ElenaPerea Cortés, JaimeHernández-Reina, CeliaCano, David A.Soto Moreno, AlfonsoAcromegalyCost analysisPasireotidePegvisomantRadiotherapy[Introduction] Acromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.[Objectives] To assess the use of pasireotide and pegvisomant in a third-level center under routine clinical practice.[Methods] Acromegaly patients that had been treated with pasireotide and/or pegvisomant were included in (A) a cross-sectional study (two years after starting these drugs) to analyze the cost of acromegaly, hormone replacement, and type 2 diabetes mellitus (T2DM) treatments, and the cost of surgery and radiotherapy; and (B) a retrospective cohorts study (May 2006—October 2024) to analyze efficacy, safety (adverse events, fasting glucose, glycated hemoglobin, and T2DM diagnosis), and dose evolution. Descriptive statistics were 10% trimmed means and standard deviation. Two-tailed hypothesis testing with Yuen’s t and Fisher’s test had a P < 0.05 significance.[Results] 25 participants were included in the transversal study and 31 participants in the longitudinal study. A typical patient with a poorly granulated GH-producing adenoma underwent in-center surgery once and received radiotherapy. In the transversal study, total pharmacological cost was 34,139.29 (13,472.09) €/person/year, with 33,874.88 (13,468.36) €/person/year for second-line acromegaly drugs. Pasireotide displayed 9,423.26 €/person/year worth of savings (P = .12), reaching 30,415.98 €/person/year at high dose (P < 0.001). In the longitudinal study, pasireotide dose was reduced (P = .06) regardless of treatment modality. Pasireotide affected carbohydrate metabolism (P = .001), but the effect was generally mild.[Conclusions] Pasireotide was found to be a more cost-effective option in patients with first-line treatment failure.The author(s) declare that no financial support was received for the research and/or publication of this article.Peer reviewedFrontiers MediaRemón-Ruiz, Pablo [0000-0002-4551-8159]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252025info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/391046reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.3389/fendo.2025.1573721https://doi.org/10.3389/fendo.2025.1573721Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3910462026-05-22T06:33:51Z
dc.title.none.fl_str_mv Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
title Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
spellingShingle Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
Venegas Moreno, Eva
Acromegaly
Cost analysis
Pasireotide
Pegvisomant
Radiotherapy
title_short Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
title_full Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
title_fullStr Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
title_full_unstemmed Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
title_sort Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study
dc.creator.none.fl_str_mv Venegas Moreno, Eva
Jiménez-Sánchez, Andrés
Remón-Ruiz, Pablo
Dios, Elena
Perea Cortés, Jaime
Hernández-Reina, Celia
Cano, David A.
Soto Moreno, Alfonso
author Venegas Moreno, Eva
author_facet Venegas Moreno, Eva
Jiménez-Sánchez, Andrés
Remón-Ruiz, Pablo
Dios, Elena
Perea Cortés, Jaime
Hernández-Reina, Celia
Cano, David A.
Soto Moreno, Alfonso
author_role author
author2 Jiménez-Sánchez, Andrés
Remón-Ruiz, Pablo
Dios, Elena
Perea Cortés, Jaime
Hernández-Reina, Celia
Cano, David A.
Soto Moreno, Alfonso
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Remón-Ruiz, Pablo [0000-0002-4551-8159]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Acromegaly
Cost analysis
Pasireotide
Pegvisomant
Radiotherapy
topic Acromegaly
Cost analysis
Pasireotide
Pegvisomant
Radiotherapy
description [Introduction] Acromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/391046
url http://hdl.handle.net/10261/391046
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at DOI https://doi.org/10.3389/fendo.2025.1573721
https://doi.org/10.3389/fendo.2025.1573721
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411588349362176
score 15.811543

Similares en LA Referencia